Roxadustat in CKD and transplant patients: A new era in anemia management
The aim of this study was to evaluate the efficacy and safety of Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the management of anemia in patients with chronic kidney disease (CKD), including hemodialysis-dependent (HDD), non-dialysis-dependent (NDD), and renal...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Liaquat University of Medical and Health Sciences
2025-03-01
|
| Series: | Liaquat Medical Research Journal |
| Subjects: | |
| Online Access: | http://121.52.154.206/index.php/LMRJ/article/view/1284 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850130978123546624 |
|---|---|
| author | Muhammad Tassaduq Khan Sidrah Rashid Syed Hasan farooq Sabahat Sarfaraz Rashid bin Hamid Naranjan Lal |
| author_facet | Muhammad Tassaduq Khan Sidrah Rashid Syed Hasan farooq Sabahat Sarfaraz Rashid bin Hamid Naranjan Lal |
| author_sort | Muhammad Tassaduq Khan |
| collection | DOAJ |
| description |
The aim of this study was to evaluate the efficacy and safety of Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the management of anemia in patients with chronic kidney disease (CKD), including hemodialysis-dependent (HDD), non-dialysis-dependent (NDD), and renal transplant recipients (RTRs). This was a prospective cross-sectional study was conducted at Dow University of Health Sciences, Karachi, Pakistan, from August 2024 to January 2025. A total of 55 patients were enrolled and treated with Roxadustat, beginning with a dose of 100 mg thrice weekly for the initial 4 weeks, followed by 70 mg thrice weekly. The primary outcome was the achievement of a hemoglobin (Hb) target of ?10 g/dL within 6 weeks. The safety profile was assessed by monitoring adverse events, including myocardial infarction. A total of 55 patients were recruited in the study. Of these, 19 were hemodialysis-dependent (HDD), 31 were non-dialysis-dependent (NDD), and 5 were renal transplant recipients (RTRs). The hemoglobin target of 10 g/dL within 6 weeks was achieved in 48 patients (87.3%). Among the successful cases, 18 were HDD patients, 26 were NDD patients, and 3 were RTRs. The remaining 7 patients (12.7%) did not achieve the target hemoglobin level within the specified timeframe. Adverse events were observed in 3 patients (5.4%), all of whom experienced myocardial infarction. This included 2 HDD patients and 1 NDD patient. No adverse events were reported in the RTR group. Overall, Roxadustat was well-tolerated, with a structured dose adjustment from 100 mg thrice weekly to 70 mg thrice weekly ensuring sustained hemoglobin levels. Roxadustat appears to be an effective and generally safe therapeutic option for managing anemia in CKD patients, including those who are HDD, NDD, or RTRs. However, monitoring for cardiovascular events, such as myocardial infarction, is essential in these patients.
|
| format | Article |
| id | doaj-art-dcf8a72da7ad4baba9a2eb3acbef2cd8 |
| institution | OA Journals |
| issn | 2664-5734 2709-5878 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Liaquat University of Medical and Health Sciences |
| record_format | Article |
| series | Liaquat Medical Research Journal |
| spelling | doaj-art-dcf8a72da7ad4baba9a2eb3acbef2cd82025-08-20T02:32:33ZengLiaquat University of Medical and Health SciencesLiaquat Medical Research Journal2664-57342709-58782025-03-017110.38106/LMRJ.2025.7.1-08Roxadustat in CKD and transplant patients: A new era in anemia managementMuhammad Tassaduq Khan0Sidrah Rashid1Syed Hasan farooq2Sabahat SarfarazRashid bin HamidNaranjan Lal3DOW UNIVERSITY OF HEALTH SCIENCESDow university Hospital Dow university Hospital Dow University of Health Sciences The aim of this study was to evaluate the efficacy and safety of Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the management of anemia in patients with chronic kidney disease (CKD), including hemodialysis-dependent (HDD), non-dialysis-dependent (NDD), and renal transplant recipients (RTRs). This was a prospective cross-sectional study was conducted at Dow University of Health Sciences, Karachi, Pakistan, from August 2024 to January 2025. A total of 55 patients were enrolled and treated with Roxadustat, beginning with a dose of 100 mg thrice weekly for the initial 4 weeks, followed by 70 mg thrice weekly. The primary outcome was the achievement of a hemoglobin (Hb) target of ?10 g/dL within 6 weeks. The safety profile was assessed by monitoring adverse events, including myocardial infarction. A total of 55 patients were recruited in the study. Of these, 19 were hemodialysis-dependent (HDD), 31 were non-dialysis-dependent (NDD), and 5 were renal transplant recipients (RTRs). The hemoglobin target of 10 g/dL within 6 weeks was achieved in 48 patients (87.3%). Among the successful cases, 18 were HDD patients, 26 were NDD patients, and 3 were RTRs. The remaining 7 patients (12.7%) did not achieve the target hemoglobin level within the specified timeframe. Adverse events were observed in 3 patients (5.4%), all of whom experienced myocardial infarction. This included 2 HDD patients and 1 NDD patient. No adverse events were reported in the RTR group. Overall, Roxadustat was well-tolerated, with a structured dose adjustment from 100 mg thrice weekly to 70 mg thrice weekly ensuring sustained hemoglobin levels. Roxadustat appears to be an effective and generally safe therapeutic option for managing anemia in CKD patients, including those who are HDD, NDD, or RTRs. However, monitoring for cardiovascular events, such as myocardial infarction, is essential in these patients. http://121.52.154.206/index.php/LMRJ/article/view/1284Roxadustat, Anemia, Chronic Kidney Disease, Hemoglobin, Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, Safety, Efficacy, Hemodialysis, Non-Dialysis, Renal Transplant. |
| spellingShingle | Muhammad Tassaduq Khan Sidrah Rashid Syed Hasan farooq Sabahat Sarfaraz Rashid bin Hamid Naranjan Lal Roxadustat in CKD and transplant patients: A new era in anemia management Liaquat Medical Research Journal Roxadustat, Anemia, Chronic Kidney Disease, Hemoglobin, Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, Safety, Efficacy, Hemodialysis, Non-Dialysis, Renal Transplant. |
| title | Roxadustat in CKD and transplant patients: A new era in anemia management |
| title_full | Roxadustat in CKD and transplant patients: A new era in anemia management |
| title_fullStr | Roxadustat in CKD and transplant patients: A new era in anemia management |
| title_full_unstemmed | Roxadustat in CKD and transplant patients: A new era in anemia management |
| title_short | Roxadustat in CKD and transplant patients: A new era in anemia management |
| title_sort | roxadustat in ckd and transplant patients a new era in anemia management |
| topic | Roxadustat, Anemia, Chronic Kidney Disease, Hemoglobin, Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, Safety, Efficacy, Hemodialysis, Non-Dialysis, Renal Transplant. |
| url | http://121.52.154.206/index.php/LMRJ/article/view/1284 |
| work_keys_str_mv | AT muhammadtassaduqkhan roxadustatinckdandtransplantpatientsanewerainanemiamanagement AT sidrahrashid roxadustatinckdandtransplantpatientsanewerainanemiamanagement AT syedhasanfarooq roxadustatinckdandtransplantpatientsanewerainanemiamanagement AT sabahatsarfaraz roxadustatinckdandtransplantpatientsanewerainanemiamanagement AT rashidbinhamid roxadustatinckdandtransplantpatientsanewerainanemiamanagement AT naranjanlal roxadustatinckdandtransplantpatientsanewerainanemiamanagement |